HemaQuest’s investor syndicate includes Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.
The financing is intended to help advance HemaQuest’s two lead products, HQK-1001 and HQK-1004, into pre-pivotal Phase 2 clinical trials.
HQK-1001 is an orally administered small molecule therapeutic being developed to treat the two most common hemoglobin disorders, sickle cell disease and beta thalassemia. The drug candidate has advanced through Phase 1 clinical trials and is currently undergoing testing in proof of concept clinical studies in patients with sickle cell disease and beta thalassemia.
HQK-1004 is a unique therapy designed to treat hematologic malignancies associated with viruses. The drug candidate will begin testing in a corporate sponsored Phase 2 clinical trial in the near future.
In conjunction with the financing, Naheed Misfeldt, Partner at Aberdare Ventures, has joined HemaQuest’s Board of Directors.